CAJ | 학술논문

目的观察国产卡铂注射液的疗效及毒性，并与卡铂粉针剂比较。方法全组121例小细胞肺癌(SCLC)、非小细胞肺癌(NSCLC)及乳腺癌(BC)患者随机进入卡铂注射液组(验证组)及粉针剂组(对照组)，分别给予CE、CIE及CAF方案化疗，两组所用药物及剂量完全一致。结果验证组与对照组SCLC的有效率分别为83.7%与72.2%(P＞0.05),NSCLC分别为11.5%与22.2%(P＞0.05)，BC分别为71.4%与66.7%(P＞0.05)。两组毒性反应主要为骨髓抑制及胃肠道反应。验证组与对照组白细胞下降分别为82.4%及88.2%，血小板下降分别为42.4%与55.9%，血红蛋白下降分别为61.2%与73.5%，毒性多为Ⅰ～Ⅱ度。恶心呕吐发生率分别为88.2%和91.2%，其中Ⅲ～Ⅳ度仅占9.4%与8.8%，两组间差异无显著意义。结论国产卡铂注射液疗效确切，有效率和毒性反应均与粉针剂相当，临床使用方便，价格低于同类进口药物，值得临床应用。
목적관찰국산잡박주사액적료효급독성，병여잡박분침제비교。방법전조121례소세포폐암(SCLC)、비소세포폐암(NSCLC)급유선암(BC)환자수궤진입잡박주사액조(험증조)급분침제조(대조조)，분별급여CE、CIE급CAF방안화료，량조소용약물급제량완전일치。결과험증조여대조조SCLC적유효솔분별위83.7%여72.2%(P＞0.05),NSCLC분별위11.5%여22.2%(P＞0.05)，BC분별위71.4%여66.7%(P＞0.05)。량조독성반응주요위골수억제급위장도반응。험증조여대조조백세포하강분별위82.4%급88.2%，혈소판하강분별위42.4%여55.9%，혈홍단백하강분별위61.2%여73.5%，독성다위Ⅰ～Ⅱ도。악심구토발생솔분별위88.2%화91.2%，기중Ⅲ～Ⅳ도부점9.4%여8.8%，량조간차이무현저의의。결론국산잡박주사액료효학절，유효솔화독성반응균여분침제상당，림상사용방편，개격저우동류진구약물，치득림상응용。
Objective　To observe the efficacy and side effects of carboplatin solution in comparison with carboplatin powder.　Methods　A multicenter, open randomized controlled trial was carried out. A total of 121 patients with small cell lung cancer(SCLC), non-small cell lung cancer (NSCLC) and breast cancer (BC) were randomized into carboplatin injection group (study group) and carboplatin powder group (control group), treated with CE, CIE and CAF protocol, respectively. The same drugs and dosage were used in the two groups.　Results The response rate of the study group and the control group was 94% and 67% in SCLC (P＞0.05), 12% and 22% in NSCLC (P＞0.05) and 71.4% and 67% in BC (P＞0.05), respectively. The major side effects were myelosuppression and gastrointestinal reactions, the frequency and intensity of which were statistically not different in the 2 groups of patients.　Conclusion　Carboplatin solution is as effective as carboplatin powder for the treatment of cancer.